NBI-1117567, an investigational, oral, M1/M4 (M1 preferring) selective muscarinic agonist, is intended for the potential treatment of neurological and neuropsychiatric conditions.
Eiry W Roberts, M.D.,
.
(C) 2024 M2 COMMUNICATIONS, source
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
142.3 USD | +0.27% | +4.09% | +7.99% |
NBI-1117567, an investigational, oral, M1/M4 (M1 preferring) selective muscarinic agonist, is intended for the potential treatment of neurological and neuropsychiatric conditions.
Eiry W Roberts, M.D.,
.
(C) 2024 M2 COMMUNICATIONS, source
1st Jan change | Capi. | |
---|---|---|
+7.99% | 14.32B | |
+9.42% | 115B | |
+11.84% | 106B | |
-2.71% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+36.24% | 12.42B | |
-24.95% | 8.23B |